7 Results for "

myeloid neoplasms

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "myeloid neoplasms" in MCE Product Catalog:

Cat. No.: HY-171792
Synonyms: ORM-6151
BMS-986497 (ORM-6151) is a CD33-targeting antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells and induces GSPT1 protein degradation. BMS-986497 shows potential for research on acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-12854
CAS No.: 868169-64-6
Purity:  99.43%
Synonyms: GRN163L
Target:  

Telomerase Apoptosis

Research Areas:  

Cardiovascular Disease Cancer

Imetelstat (GRN163L) is a 13-mer oligonucleotide and competitive Telomerase inhibitor. Imetelstat binds with high affinity to the template region of the RNA component of human telomerase. Imetelstat induces Apoptosis. Imetelstat is capable of selectively eliminating myelofibrosis hematopoietic stem cells. Imetelstat leads to the loss of a cancer cell's ability to maintain telomere length, resulting in the inhibition of cell proliferation .
loading...
    loading...
Cat. No.: HY-155412
CAS No.: 2675452-91-0
Purity:  ≥99.0%
Research Areas:  

Cancer

PFI-6 is a selective MLLT1 and MLLT3 YEATS domain probe with IC50 values of 0.14 μM and 0.16 μM, respectively. PFI-6 is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-164393
CAS No.: 1035199-04-2
Target:  

JAK Bcr-Abl Apoptosis

Research Areas:  

Cancer

ON044580 is a non–ATP-competitive JAK2 and BCR-ABL kinases inhibitor. ON044580 inhibits wild-type (WT) and V617F mutant JAK2 with IC50 values of 1.23 μM, 1.09 μM, respectively. ON044580 also inhibits both WT and T315I mutant BCR-ABL kinases., ON044580 blocks the IL-3–mediated phosphorylation of JAK2 and STAT5, induces apoptosis in Imatinib (HY-15463)-resistant chronic myeloid leukemia (CML). ON044580 can be used for the study of CML, myelodysplasia (MDS) and other myeloproliferative neoplasms .
loading...
    loading...
Cat. No.: HY-113902
CAS No.: 109628-38-8
Target:  

CRM1

Research Areas:  

Cancer

(2-(β-Piperidinoethyl)-9-hydroxyellipticinium chloride (compound 1AA) is a SETBP1 inhibitor that disrupts the interaction between SETBP1 and XPO1. (2-(β-Piperidinoethyl)-9-hydroxyellipticinium chloride inhibits colony formation, induces differentiation/cytotoxicity, and downregulates the transcription of Setbpl target genes. (2-(β-Piperidinoethyl)-9-hydroxyellipticinium chloride improves survival and reduces the spleen size of leukemic mice. (2-(β-Piperidinoethyl)-9-hydroxyellipticinium chloride can be used for myeloid neoplasms and solid tumors research .
loading...
    loading...
Cat. No.: HY-180561
CAS No.: 3076807-15-0
Research Areas:  

Cancer

WWQ-03-012 is a selective DESI2 inhibitor with an IC50 of 47.3 nM. WWQ-03-012 binds covalently to DESI2, blocks its enzymatic activity, and inhibits DESI2-mediated deSUMOylation, deubiquitination and stabilization of mutant JAK2, thereby promoting the complete degradation of mutant JAK2 via the intracellular ubiquitin-proteasome system and inducing apoptosis, while exerting no significant effect on wild-type JAK2. WWQ-03-012 can be used for research on myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML), especially for hematological malignancies carrying the JAK2-V617F mutation and those resistant to Ruxolitinib (HY-50856) .
loading...
    loading...
Cat. No.: HY-159846S
Synonyms: FCN-159-d
Luvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia .
loading...
    loading...